SFSIG
TAK icon

San Francisco Sentry Investment Group’s Takeda Pharmaceutical TAK Stock Holding History

San Francisco Sentry Investment Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8,663
Closed -$149K – 947
2019
Q3 		$149K Hold
8,663
– – 0.07% 231
2019
Q2 		$153K Hold
8,663
– – 0.07% 224
2019
Q1 		$176K Buy
+8,663
New +$174K 0.08% 228

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

San Francisco Sentry Investment Group's TAK Position: Q4 2019 in Review

San Francisco Sentry Investment Group sold out of Takeda Pharmaceutical (TAK) in Q4 2019, closing a stake of 8,663 shares — an estimated $149K sold.

San Francisco Sentry Investment Group first reported a position in TAK in Q1 2019 and held it in 3 quarters. The position peaked at $176K in Q1 2019. 339 funds tracked by Wall St. Rank hold TAK as of Q4 2019.

  • San Francisco Sentry Investment Group reported no remaining Takeda Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 8,663 Takeda Pharmaceutical shares in Q4 2019, an estimated $149K.
  • San Francisco Sentry Investment Group first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 3 quarters.
  • San Francisco Sentry Investment Group's Takeda Pharmaceutical position peaked at $176K in Q1 2019.
  • 339 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q4 2019, filed 30 Jan 2020.